Cell study identifies pathway connecting telomere length, myelodysplastic syndromes | Study links DNMT3A mutations with increased risk of leukemia relapse | Marrow-derived stem cells linked with faster bone healing in trial
May 21, 2015
AABB SmartBrief
News for the transfusion medicine and cellular therapy community

Top Story
Cell study identifies pathway connecting telomere length, myelodysplastic syndromes
A study of human and mouse cells found that telomere degradation inhibits expression of the SRSF2 gene, which in turn interferes with the ability of common myeloid progenitor cells to differentiate. Researchers at the University of Texas MD Anderson Cancer Center said their work suggests strategies that reduce DNA damage may help treat myelodysplastic syndromes. The findings were reported in the journal Cancer Cell. BioNews Texas (5/18)
Share: LinkedInTwitterFacebookGoogle+Email
Science & Health
Study links DNMT3A mutations with increased risk of leukemia relapse
A genetic analysis of samples from 914 patients with acute myeloid leukemia found that 30% had a mutation in the DNMT3A gene. The presence of a DNMT3A mutation was associated with increased risk of relapse and mortality, according to the study in the Journal of Clinical Oncology. Eighty percent of patients with DNMT3A mutations also had a mutation in the NPM1 gene. CancerNetwork.com (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Marrow-derived stem cells linked with faster bone healing in trial
A controlled trial presented at the European Congress of Endocrinology found that the addition of stem cells from human bone marrow was associated with faster healing among diabetes patients with bone fractures. Researchers used cells from donors without diabetes. Diabetes.co.uk (U.K.) (5/19)
Share: LinkedInTwitterFacebookGoogle+Email
Emerging Trends
Researchers analyze trends in sepsis readmissions
Researchers with Bellevue Hospital in New York reported at a meeting of the American Thoracic Society that the rate of readmission for patients with severe sepsis was comparable to the readmission rates for heart failure and pneumonia. From July 2011 to July 2014, the study team found readmission rates of 12% to 15%, depending on what methods were used to identify cases of severe sepsis. BeckersHospitalReview.com (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Blood tests developed for irritable bowel syndrome
A researcher has developed two blood tests for the detection of irritable bowel syndrome, according to a study in the journal PLOS ONE. The assays identify elevated levels of the antibodies anti-CdtB and anti-vinculin, which react to toxins related to food poisoning. Medical News Today (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Industry News & Practice
Gene therapy developer secures $70.5M from funding round
A funding round has brought in $70.5 million for Regenxbio, a Washington, D.C.-based firm specializing in the development of gene therapies. The company intends to use the money to support clinical trials of its lead programs and to expand its NAV technology-based therapeutics. BioSpace (San Francisco) (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
Government & Regulatory
Hepatitis C combination from Bristol-Myers gains amended breakthrough status
Bristol-Myers Squibb's hepatitis C drug combination daclatasvir and sofosbuvir received amended breakthrough therapy designation from the FDA as a treatment for hepatitis C patients with advanced cirrhosis or recurrent infection following liver transplant. The decision was based on positive results from a late-stage trial. The FDA is also reviewing a new drug application for the combination to treat hepatitis C genotype 3. Pharmacy Times online (5/20), eMPR.com (5/20)
Share: LinkedInTwitterFacebookGoogle+Email
CMS to discuss ICD-10, ICD-10-PCS Section X in national call
A national call will be hosted by the CMS on June 18 to discuss resources and strategies to help health care professionals convert to ICD-10 codes. The ICD-10-PCS Section X for new technologies, which hospitals will use, also will be covered in the call. Health Industry Washington Watch blog (5/19)
Share: LinkedInTwitterFacebookGoogle+Email
AABB Patient Blood Management Learning Modules, a Must-have Resource
Obtaining clinical leadership and administration buy-in, providing targeted education, and fostering a cultural change within your institution are challenges to implementing a patient blood management (PBM) program. Overcome these obstacles with the help of AABB PBM Learning Modules — self-paced, interactive web-based tools. Purchase today!
Association News
AABB white paper helps clinicians make business case for PBM program
AABB's new white paper, "Building a Better Patient Blood Management Program," starts with a discussion of how to make a convincing business case for implementing a PBM program, including the key elements of a business plan and creative solutions to commonly encountered problems. Providing education about PBM and engaging staff in the development of the program could help overcome resistance. In addition, an informal or pilot PBM program could help clinicians demonstrate improved patient outcomes and financial savings. Although the logistics associated with initiating a PBM program may seem challenging at first, transfusion committees may be able to play a key role in planning, implementing and maintaining the program.
Share: LinkedInTwitterFacebookGoogle+Email
powered by
Director of Collections
Assistant/Associate Director, Blood Transfusion Service, Massachusetts General Hospital
Clinical Laboratory Scientist
Audit Manager
Staff Scientist
He who wishes to be obeyed must know how to command."
-- Niccolo Machiavelli,
historian and writer
Share: LinkedInTwitterFacebookGoogle+Email
Learn more about AABB® ->Homepage | Join AABB | Conferences | Marketplace | AABB CareerLink
Subscriber Tools
Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
Editor:  Tom Parks
Advertising:  Meryl Harold
  P: 202.407.7828

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2015 SmartBrief, Inc.®
Privacy policy |  Legal Information